FLASH Radiation Combination Therapy for Tumor Kill With Tissue Sparing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Radiation therapy for cancer is limited by tumor cell resistance and normal tissue toxicity, with conventional radiation inducing immune-suppressive microenvironments that counteract therapeutic effects and result in systemic toxicity.
Innovation Solution
Combining ultra-high-dose-rate (FLASH) radiation with therapeutic agents, such as immune modulators and nanoparticles, to enhance tumor cell killing while minimizing normal tissue damage by altering the tumor microenvironment and sparing circulating immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional radiation therapy is used to treat tumors, then tumor cell killing is achieved, but normal tissue toxicity increases and immune-suppressive microenvironments are induced
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional dose rate radiation (typically 0.5-5 Gy/min) to ultra-high dose rate FLASH radiation (>40 Gy/sec). This parameter change in dose rate delivery fundamentally alters the biological response, achieving tumor cell killing while paradoxically sparing normal tissue from toxicity, thus resolving the contradiction between therapeutic efficacy and normal tissue protection
Solution Approach 2:
The patent employs periodic action through FLASH radiation delivery, where the entire therapeutic dose is administered in an extremely brief time window (milliseconds to seconds) rather than prolonged exposure. This ultra-short duration periodic delivery prevents the development of immune-suppressive microenvironments while maintaining tumor cell killing, addressing both the efficacy and toxicity concerns
2Reliability
If conventional radiation therapy is used to treat tumors, then tumor cell killing is achieved, but tumor resistance mechanisms develop
Solution Approach 1:
By changing the radiation delivery parameter from conventional dose rates to ultra-high FLASH dose rates, the patent creates a novel biological response that overwhelms tumor cell resistance mechanisms. The extreme speed of dose delivery prevents tumor cells from activating repair pathways and resistance mechanisms that would normally develop during slower conventional radiation therapy
3Reliability
If immune modulators are used as monotherapy to activate the immune system, then immune response is enhanced, but response rate remains limited to 20-30% of patients
Solution Approach 1:
The patent merges two distinct therapeutic approaches: FLASH radiation therapy and immune modulator therapy. This combination creates a synergistic effect where FLASH radiation acts as a potent in situ vaccine that releases tumor antigens and activates the immune system, while immune modulators enhance and sustain this response. The merging of these mechanisms overcomes the limited response rate of immune modulator monotherapy by providing both immediate tumor cell killing and sustained immune activation
4Reliability
If combination therapy with two immune modulators or immune modulator with targeted drug is used, then immune response is enhanced, but systemic normal tissue toxicity increases
Solution Approach 1:
The patent combines FLASH radiation (a localized physical therapy) with immune modulators to achieve immune system activation. This merging allows for enhanced immune response while avoiding the systemic toxicity associated with combining multiple immune modulators, because the FLASH radiation component delivers therapy locally to the tumor site without systemic exposure
Solution Approach 2:
FLASH radiation acts as an intermediary that bridges the tumor and the immune system. By using FLASH radiation to induce tumor cell death and antigen release, the patent creates a localized immune activation mechanism that avoids the need for high-dose systemic immune modulator combinations, thereby reducing systemic normal tissue toxicity while still enhancing the immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves therapeutic efficacy by increasing tumor kill and reducing normal tissue side effects, allowing for dose escalation and enhanced immune response, particularly when combined with proton therapy.
Implementation Method 1
Radiation therapy is a key therapeutic modality for patients with cancer. Radiation can be delivered to the tumor with submillimeter precision while mostly sparing normal tissue
Implementation Method 2
Another benefit of FLASH RT is that it spares circulating immune cells from radiation induced toxicity, leading to improved immune-related tumor cell killing effects
Data Source
AI summary
Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.